Targeted Cancer Therapies
This session
highlights precision oncology’s growing role
through targeted therapies that address specific genetic
mutations and cellular pathways. Experts will discuss the latest approved
targeted agents and ongoing clinical trials investigating kinase inhibitors,
PARP inhibitors, and angiogenesis blockers.
Emphasis will be
placed on resistance mechanisms and strategies to overcome them using
combination therapies. Molecular diagnostics and companion testing will also be
featured. Attendees will discover how these therapies are reshaping cancer care
paradigms.
Subtracks:
- Tyrosine Kinase Inhibitors in Solid and Haematologic Tumours
- PARP Inhibitors in BRCA-Associated Cancers
- Anti-Angiogenic Therapy
- Mechanisms of Drug Resistance and Overcoming Strategies
- Companion Diagnostics in Targeted Therapy
- Emerging Targets in Rare and Aggressive Cancers